基于无区间的复发或晚期子宫内膜癌患者后期治疗的决策
Masafumi Yasunaga1, Hideaki Yahata, Kaoru Okugawa
1Department of Gynecology and Obstetrics, Kyushu University Hospital, Fukuoka, Japan.
American journal of clinical oncology
|June 5, 2023
概括
对于复发性或晚期子宫内膜癌,含的化学疗法重复治疗显示出与博利祖马布加伦瓦提尼布相似的结果,当无间隔≥6个月时. 然而,对于较短的间隔 (<6个月),组合治疗似乎更优越.
科学领域:
- 妇科瘤学 妇科瘤学
- 医学瘤学 医学瘤学
- 临床药理学 临床药理学
背景情况:
- 复发或晚期子宫内膜癌 (REC/AEC) 构成了重大治疗挑战.
- 含化疗 (PCC) 是一种标准的再治疗选择,但其疗效根据无间隔 (PFI) 不同.
- 在KEYNOTE-775研究中,Pembrolizumab和Lenvatinib被确定为一种新的治疗选择.
研究的目的:
- 评估与PCC重新治疗的REC/AEC患者的无进展生存 (PFS) 和整体应答率 (ORR).
- 根据无区间 (PFI) 来比较PCC重复治疗与pembrolizumab加lenvatinib的疗效.
主要方法:
- 65名REC或AEC患者的回顾性分析与PCC (2005-2020年) 重新治疗.
- 对临床病理学变量的分析,包括PFI,PFS和ORR.
- 与KEYNOTE-775研究中公布的数据进行比较.
主要成果:
- 患有PFI≥6个月的患者获得了最佳ORR为43.3%和PCC的PFS为9.5个月.
- 这些结果与pembrolizumab加lenvatinib报告的结果相似.
- 与组合疗法相比,PFI <6个月的患者在PCC中显示出较低的ORR和PFS.
结论:
- 布罗利祖马布加上伦瓦提尼布可能是REC/AEC的首选治疗方法,PFI<6个月.
- 对于PFI≥6个月的患者,PCC和pembrolizumab加上lenvatinib都是可行的选择,选择可能受到前期化疗残留副作用的影响.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K